Comparación de los hallazgos histopatológicos con la respuesta clínica en los pacientes con biopsia renal consecutiva en nefritis lúpica 2008-2021
| datacite.rights | http://purl.org/coar/access_right/c_16ec | spa |
| dc.contributor.advisor | Aroca Martínez, Gustavo José | |
| dc.contributor.advisor | Guido Musso, Carlos | |
| dc.contributor.author | Villadiego Rojas, Rafael Emigdio | |
| dc.date.accessioned | 2023-02-06T20:31:54Z | |
| dc.date.available | 2023-02-06T20:31:54Z | |
| dc.date.issued | 2023 | |
| dc.description.abstract | El Lupus eritematoso sistémico (LES) es una enfermedad autoinmune inflamatoria, que involucra varios sistemas, como el renal, membranas vasculares y serosas, con un aumento significativo de la morbimortalidad. La nefritis lúpica (NL) implica peor pronóstico para los pacientes con LES, la biopsia renal es la mejor herramienta para su diagnóstico siendo un método seguro, con una baja tasa de complicaciones, que se presentan usualmente durante las primeras 24 horas. Objetivo: Evaluar la relación entre los hallazgos histopatológicos y la respuesta clínica en pacientes con nefritis lúpica que han tenido una biopsia renal consecutiva entre 2008 y 2021 Material y Métodos: Estudio observacional, analítico y retrospectivo; se analizó la base de datos de biopsia renal de la Clínica de la Costa, desde el año 2008 hasta el 2021 Resultados: La mediana del tiempo transcurrido entre la primera y la segunda biopsia renal fue de 850 días, Se encontraron diferencias significativas en el índice de cronicidad, siendo este mayor al momento de la segunda biopsia (p <0.001). Los valores de creatinina y complemento C4 fueron significativamente mayores al momento de la segunda biopsia (p-valor=0.007 y p-valor=0.005 respectivamente). Para la tasa de filtración glomerular y la proteína urinaria también se hallaron diferencias significativas, pero en estos casos los valores disminuyeron entre la primera y la segunda biopsia (p-valores = 0.002 y 0.035, respectivamente). Conclusión: La biopsia renal consecutiva puede ser una herramienta útil en NL, con baja tasa de complicaciones y con posibilidad de brindar un manejo médico óptimo basado en hallazgos histopatológicos. | spa |
| dc.description.abstract | Systemic lupus erythematosus (SLE) is an inflammatory autoimmune disease, which involves several systems, such as the renal, vascular and serous membranes, with a significant increase in morbidity and mortality. Lupus nephritis (LN) implies worse prognosis for patients with SLE, and renal biopsy is the best diagnostic tool. It is a safe method, with a low rate of complications, which usually occur during the first 24 hours. Objective: Evaluate the relationship between the histopathological findings and the clinical response of patients with lupus nephritis that have had a consecutive renal biopsy between 2008 and 2021. Material and Methods: Observational, analytical and retrospective study; the renal biopsy database of Clínica de la Costa was analyzed, from 2008 to 2021. Results: The median time elapsed between the first and second renal biopsy was 850 days, Significant differences were found in the chronicity index, being higher at the time of the second biopsy (p<0.001). Creatinine and complement C4 values were significantly higher at the time of the second biopsy (p-value=0.007 and p-value=0.005 respectively). For glomerular filtration rate and urinary protein significant differences were also found, but in these cases the values decreased between the first and second biopsy (p-values=0.002 and 0.035, respectively). Conclusion: Consecutive renal biopsy can be a useful tool in LN, with low complication rate and possibility to provide optimal medical management based on histopathological findings. | eng |
| dc.format.mimetype | spa | |
| dc.identifier.uri | https://hdl.handle.net/20.500.12442/11808 | |
| dc.language.iso | spa | spa |
| dc.publisher | Ediciones Universidad Simón Bolívar | spa |
| dc.publisher | Facultad de Ciencias de la Salud | spa |
| dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 Internacional | * |
| dc.rights.accessrights | info:eu-repo/semantics/restrictedAccess | spa |
| dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | * |
| dc.subject | Lupus eritematoso sistémico | spa |
| dc.subject | Nefritis lúpica | spa |
| dc.subject | Biopsias renal consecutivas | spa |
| dc.subject | Índice de actividad | spa |
| dc.subject | Índice de cronicidad | spa |
| dc.subject | Systemic lupus erythematosus | eng |
| dc.subject | Lupus nephritis | eng |
| dc.subject | Consecutive renal biopsies | eng |
| dc.subject | Activity index | eng |
| dc.subject | Chronicity index | eng |
| dc.title | Comparación de los hallazgos histopatológicos con la respuesta clínica en los pacientes con biopsia renal consecutiva en nefritis lúpica 2008-2021 | spa |
| dc.type.driver | info:eu-repo/semantics/other | spa |
| dc.type.spa | Otros | spa |
| dcterms.references | Brown SJ. Systemic lupus erythematosus. Nurs Times. 2003;99(40):30–2. | eng |
| dcterms.references | Khalifa M, Kaabia N, Bahri F, Ben Jazia E, Bouajina E, Omezzine Letaief A. Infection in systemic lupus erythematosus. Médecine Mal Infect. 2007 Dec 1;37(12):792–5. | eng |
| dcterms.references | J Gómez, D Palazón , G Ortega et al. Infecciones y lupus eritematoso sistémico. Análisis de factores de riesgo y pronóstico. Un estudio prospectivo (1979-1988). Rev Clin Esp. 1991;188(72):5. | spa |
| dcterms.references | Parikh S V., Alvarado A, Malvar A, Rovin BH. The Kidney Biopsy in Lupus Nephritis: Past, Present, and Future. Semin Nephrol. 2015;35(5):465–77. | eng |
| dcterms.references | Whittier WL, Korbet SM. Renal biopsy: update. Curr Opin Nephrol Hypertens. 2004 Nov;13(6):661–5. | eng |
| dcterms.references | Aroca-Martínez G, Mendoza-Jaimes J. Consecutive renal biopsy in a cohort of patients with lupus nephritis of the Colombian Caribbean. J Nephropathol. 2018;7(4):233–40. | eng |
| dcterms.references | Ayed K, Gorgi Y, Ayed-Jendoubi S, Bardi R. The involvement of HLA -DRB1*, DQA1*, DQB1* and complement C4A loci in diagnosing systemic lupus erythematosus among Tunisians. Ann Saudi Med. 2004;24(1):31–5. | eng |
| dcterms.references | Organización Panamericana de la Salud. Perfil De Los Sistemas De Salud. Colombia. Biblioteca OPS. 2008;3:1–56. | spa |
| dcterms.references | Blenkinsopp SC, Fu Q, Green Y, Madan A, Juliao P, Goldman DW, et al. Original research: Renal response at 2 years post biopsy to predict long-term renal survival in lupus nephritis: a retrospective analysis of the Hopkins Lupus Cohort. Lupus Sci Med. 2022 Aug;9(1):e000598. | eng |
| dcterms.references | González Naranjo, L. A., Vásquez Duque, G. M., Uribe Uribe, O., & Ramírez Gómez LA. Nefropatía lúpica. Presentación clínica, clasificación y tratamiento. Rev Colomb Reumatol. 2006;13(4):307-333. | spa |
| dcterms.references | Almaani S, Meara A, Rovin BH. Update on Lupus Nephritis. Clin J Am Soc Nephrol. 2017;12(5):825–35. | eng |
| dcterms.references | Aroca-Martínez GJ, Mendoza-Jaimes J, Gonzalez-Torres HJ, Dominguez-Vargas A, Martinez-Bayona Á, Navarro-Quiroz E, et al. Consecutive renal biopsy in a cohort of patients with lupus nephritis of the Colombian caribbean. J Nephropathol. 2018;7(4):233–40. | eng |
| dcterms.references | Pons-Estel BA, Catoggio LJ, Cardiel MH, Soriano ER, Gentiletti S, Villa AR, et al. The GLADEL multinational Latin American prospective inception cohort of 1,214 patients with systemic lupus erythematosus: ethnic and disease heterogeneity among “Hispanics.” Medicine (Baltimore) 2004;83(1):1–17. | eng |
| dcterms.references | Torres - Bustamante M, Palomino - Suárez D, Celis AM, Nuñez SF, Hernández - Sierra AP. Caracterización clínica de pacientes con nefropatía lúpica en Santander, la importancia de la biopsia renal. Rev Colomb Nefrol. 2019;6(2):122–9. | spa |
| dcterms.references | Mahajan A, Amelio J, Gairy K, Kaur G, Levy RA, Roth D, et al. Systemic lupus erythematosus, lupus nephritis and end-stage renal disease: a pragmatic review mapping disease severity and progression. Lupus . 2020;29(9):1011–20. | eng |
| dcterms.references | Bonett García O, Lubo Algarín R, Silvera Fonseca LM, Aroca Martínez G. Factores Predictores de Respuesta a Tratamiento de Nefritis Lúpica en Pacientes Adultos Biopsiados en la Clínica de la Costa de Barranquilla (Atlántico-Colombia) durante el período 2008-2014. Biociencias. 2015;10(2):107–17. | spa |
| dcterms.references | Moroni G, Quaglini S, Radice A, Trezzi B, Raffiotta F, Messa P, et al. The value of a panel of autoantibodies for predicting the activity of lupus nephritis at time of renal biopsy. J Immunol Res. 2015;2015. | eng |
| dcterms.references | J. W. Systemischer Lupus erythematodes. Dtsch Medizinische Wochenschrift. 2006;131(6). | eng |
| dcterms.references | Oku K, Atsumi T. Systemic lupus erythematosus: nothing stale her infinite variety. Mod Rheumatol. 2018 Sep 3;28(5):758–65. | eng |
| dcterms.references | Mace GG, Protat A, Humphries RS et al. Classification of Systemic lupus erythematosus: Systemic Lupus International Collaborating Clinic versus American College of Rheumatology criteria. Laryngoscope. 2014;1:2-31. | eng |
| dcterms.references | Giannico G, Fogo AB. Lupus nephritis: is the kidney biopsy currently necessary in the management of lupus nephritis? Clin J Am Soc Nephrol. 2013 Jan 7;8(1):138–45. | eng |
| dcterms.references | Malvar A, Pirruccio P, Alberton V, Lococo B, Recalde C, Fazini B, et al. Histologic versus clinical remission in proliferative lupus nephritis. Nephrol Dial Transplant. 2017;32(8):1338–44. | eng |
| dcterms.references | Tesar V, Hruskova Z. Understanding Histolopathologic Characteristics to Predict Renal Outcomes in Lupus Nephritis. Clin J Am Soc Nephrol. 2017;12(5):711–2. | eng |
| dcterms.references | Furie R, Rovin BH, Houssiau F, Malvar A, Teng YKO, Contreras G, et al. Two-Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis. N Engl J Med. 2020;383(12):1117–28. | eng |
| dcterms.references | Hahn BH, McMahon MA, Wilkinson A, Wallace WD, Daikh DI, Fitzgerald JD, et al. American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res (Hoboken). 2012 ;64(6):797–808. | eng |
| dcterms.references | Moroni G, Depetri F, Ponticelli C. Lupus nephritis: When and how often to biopsy and what does it mean? J Autoimmun]. 2016;74:27–40. | eng |
| dcterms.references | Narváez J, Ricse M, Gomà M, Mitjavila F, Fulladosa X, Capdevila O, et al. The value of repeat biopsy in lupus nephritis flares. Medicine (Baltimore). 2017 Jun 1 [cited 2022 Oct 9];96(24). | eng |
| dcterms.references | Daleboudt GMN, Bajema IM, Goemaere NNT, Van Laar JM, Bruijn JA, Berger SP. The clinical relevance of a repeat biopsy in lupus nephritis flares. Nephrol Dial Transplant. 2009;24(12):3712–7. | eng |
| dcterms.references | Obrișcă B, Vornicu A, Procop A, Herlea V, Terinte-Balcan G, Gherghiceanu M, et al. A Histology-Guided Approach to the Management of Patients with Lupus Nephritis: Are We There Yet? Biomedicines. 2022;10(6). | eng |
| dcterms.references | Anders H-J. Re-biopsy in lupus nephritis. Ann Transl Med [Internet]. 2018;6(Suppl 1):S41–S41. | eng |
| dcterms.references | Nossent HC, Henzen‐Logmans SC, Vroom TM, et al. Contribution of renal biopsy data in predicting outcome in lupus nephritis. Analysis of 116 patients. Arthritis Rheum. 1990;33(7):970–7. | eng |
| dcterms.references | De Rosa M, Azzato F, Toblli JE, De Rosa G, Fuentes F, Nagaraja HN, et al. A prospective observational cohort study highlights kidney biopsy findings of lupus nephritis patients in remission who flare following withdrawal of maintenance therapy. Kidney Int. 2018;94(4):788–94. | eng |
| oaire.version | info:eu-repo/semantics/acceptedVersion | spa |
| sb.programa | Especialización en Nefrología | spa |
| sb.sede | Sede Barranquilla | spa |